GSK plc (LSE/NYSE: GSK) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation (ODD) to risvutatug rezetecan (also known as Ris-Rez), an investigational B7-H3-targeted antibody-drug conjugate (ADC), for the treatment of small-cell lung cancer (SCLC).
This milestone marks the sixth global regulatory designation for the asset, reinforcing its potential as a transformational therapy for aggressive solid tumors. The designation is supported by preliminary clinical data from the Phase I ARTEMIS-001 trial, which demonstrated durable responses in patients with extensive-stage small-cell lung cancer (ES-SCLC).
Clinical & Regulatory Milestone Summary
The following table outlines the current clinical status and the rapid regulatory momentum of risvutatug rezetecan:
| Feature | Details |
| Drug Name | Risvutatug rezetecan (Ris-Rez / GSK’227) |
| Mechanism of Action | B7-H3-targeted ADC with a topoisomerase inhibitor payload |
| Supporting Trial | Phase I ARTEMIS-001 (Early clinical data) |
| Pivotal Trial | Phase III Global Trial (NCT07099898) – Started Aug 2025 |
| Partnership | Exclusive worldwide rights (ex-China) from Hansoh Pharma |
| Key Indications | SCLC, Prostate Cancer, Colorectal Cancer, Osteosarcoma |
A Critical Unmet Need in Japan
Lung cancer remains the second most common cancer in Japan, with SCLC accounting for approximately 10-15% of all cases. The prognosis for patients with the extensive-stage form of the disease (ES-SCLC) is notably poor:
- 70% of SCLC patients are diagnosed at the extensive stage.
- High Relapse Rates: Most patients relapse following initial treatment.
- Survival Gap: The current median overall survival with standard-of-care for relapsed patients is only 8 months.
Deep Insights: Therapeutic Potential and Strategy
The granting of ODD in Japan provides GSK with several strategic advantages, including potential tax incentives and a period of market exclusivity, which are critical for rare or difficult-to-treat diseases like SCLC.
1. Targeting B7-H3: Ris-Rez utilizes a fully human monoclonal antibody to target B7-H3, a protein frequently overexpressed in several solid tumors. By linking this to a potent topoisomerase inhibitor payload, the ADC is designed to deliver cell-killing agents directly to the tumor site while minimizing systemic impact.
2. Accelerated Development: GSK’s global Phase III trial (NCT07099898) for relapsed ES-SCLC was initiated in August 2025, just months before this latest Japanese designation. This suggests a highly aggressive development timeline aimed at addressing the 8-month survival barrier currently faced by patients.
3. Expanding Oncology Footprint: Beyond SCLC, GSK is actively investigating Ris-Rez in prostate and colorectal cancers, indicating that the B7-H3 mechanism may serve as a cornerstone for GSK’s broader ADC oncology portfolio.
Merck KGaA Acquires Bio-Techne to Advance ProteinSimple and RNAscope Workflows in $11.3 Billion Deal
Merck KGaA has entered into a definitive agreement to acquire Bio-Techne for US$73 per share in cash, representing an enterprise value of US$11.3 billion to […]
Pfizer Inc. Announces Milestone as FDA Approves Pfizer’s Ibrance Regimen for Advanced Breast Cancer Frontline Maintenance
Pfizer Inc. announced the landmark FDA expansion of IBRANCE (palbociclib) in combination with anti-HER2 and endocrine therapies for HR+, HER2+ metastatic breast cancer frontline maintenance […]
Eli Lilly Completes Acquisition of Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonist Therapies
Eli Lilly and Company has announced the successful completion of its acquisition of Centessa Pharmaceuticals plc, integrating a clinical-stage portfolio of orexin receptor 2 agonists […]
About Risvutatug Rezetecan
Risvutatug rezetecan is a novel investigational ADC. Under a licensing agreement with Hansoh Pharma, GSK holds the rights to progress the clinical development and commercialization of the drug globally, excluding Mainland China, Hong Kong, Macau, and Taiwan.
